Documentos de Lambrinoudaki I. | REDI

Regresar

Mostrando 10 resultados de: 12

Filtros aplicados

Objetivos de Desarrollo Sostenible: "ODS 10: Reducción de las desigualdades"

Subtipo de publicación

Publisher

Área temáticas

Enfermedades(9)

Ginecología, obstetricia, pediatría, geriatría(8)

Farmacología y terapéutica(5)

Fisiología humana(3)

Medicina y salud(2)

Área de conocimiento

Ginecología(6)

Medicina interna(4)

Enfermedad cardiovascular(1)

Salud pública(1)

Objetivos de Desarrollo Sostenible

ODS 3: Salud y bienestar(12)

ODS 5: Igualdad de género(9)

ODS 17: Alianzas para lograr los objetivos(3)

Año de Publicación

Origen

Palabras Claves

Bisphosphonates(2)

OSTEOPOROSIS(2)

Advanced age(1)

Advanced parental age(1)

Bisphosphonates or denosumab discontinuation and risk of fractures: Response to the Letter by Anastasilakis et al.

Palabras claves:

Anagnostis P., Ceausu I., Depypere H., Faustino R. Pérez-López, Goulis D.G., Lambrinoudaki I., Mintziori G., Mueck A., Paschou S.A., Rees M., Senturk L.M., Simoncini T., Stevenson J.C., Stute P., Trémollieres F.A.

EMAS clinical guide: Low-dose vaginal estrogens for postmenopausal vaginal atrophy

Abstract: Vaginal atrophy is common in postmenopausal women. This clinical guide provides the evidence for the

Palabras claves:

Low-dose, Postmenopausal, Vaginal atrophy, Vaginal estrogens

Ceasu I., Depypere H., Erel T., Faustino R. Pérez-López, Lambrinoudaki I., Rees M., Schenck-Gustafsson K., Simoncini T., Trémollieres F.A., van der Schouw Y.T.

EMAS clinical guide: Vulvar lichen sclerosus in peri and postmenopausal women

Abstract: Introduction: Vulvar lichen sclerosus (LS) is a chronic inflammatory disease which affects genital l

Palabras claves:

Calcineurin inhibitors, Clobetasol propionate, Corticosteroids, dyspareunia, Lichen sclerosus, Pimecrolimus, pruritus, Tacrolimus, Testosterone, Vulvar kraurosis

Ceausu I., Depypere H., Faustino R. Pérez-López, Lambrinoudaki I., Rees M., Schenck-Gustafsson K., Simoncini T., Tamer Erel C., Trémollieres F.A., van der Schouw Y.T.

EMAS position statement: Late parenthood

Abstract: Introduction: During the last decades, couples in Europe have been delaying parenthood, mainly dueto

Palabras claves:

Advanced age, Advanced parental age, Female infertility, Late parenthood, Male infertility, Pregnancy Complications

Ceausu I., Depypere H., Faustino R. Pérez-López, Goulis D.G., Kolibianakis E.M., Lambrinoudaki I., Mintziori G., Rees M., Schenck-Gustafsson K., Simoncini T., Tamer Erel C., Tarlatzis B.C., Trémollieres F.A., van der Schouw Y.T.

EMAS position statement: Management of uterine fibroids

Abstract: Introduction Uterine fibroids (also termed leiomyomas or myomas) are the most common tumors of the f

Palabras claves:

Fibroids, Gn-RH analogs, High-intensity focused ultrasound, hysterectomy, Myomectomy, Ulipristal, Uterine artery embolization

Ceausu I., Depypere H., Erel T., Faustino R. Pérez-López, Lambrinoudaki I., Ornat L., Rees M., Schenck-Gustafsson K., Simoncini T., Trémollieres F.A.

EMAS position statement: Testosterone replacement therapy in the aging male

Abstract: Introduction Late-onset hypogonadism (LOH) represents a common clinical entity in aging males, chara

Palabras claves:

Aging male, Late-onset hypogonadism, Testosterone replacement

Ceausu I., Depypere H., Dimopoulou C., Faustino R. Pérez-López, Goulis D.G., Lambrinoudaki I., Mueck A., Rees M., Senturk L.M., Simonsini T., Stevenson J.C., Stute P., van der Schouw Y.T.

EMAS position statement: The management of postmenopausal women with vertebral osteoporotic fracture

Abstract: Introduction Osteoporotic vertebral fractures are associated with significant morbidity, excess mort

Palabras claves:

Conservative treatment, diagnosis, OSTEOPOROSIS, Surgical treatment, Vertebral fracture

Ceausu I., Depypere H., Erel T., Faustino R. Pérez-López, Lambrinoudaki I., Lambropoulou-Adamidou K., Nacopoulos C.C., Papaioannou N.A., Rees M., Schenck-Gustafsson K., Simoncini T., Trémollieres F.A., Triantafyllopoulos I.K., van der Schouw Y.T.

Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement

Abstract: Background Bisphosphonates and denosumab are used extensively in the treatment of postmenopausal ost

Palabras claves:

Alendronate, Bisphosphonates, Denosumab, Drug holiday, Risedronate, Zoledronic acid

Anagnostis P., Ceausu I., Depypere H., Faustino R. Pérez-López, Goulis D.G., Lambrinoudaki I., Mintziori G., Mueck A., Paschou S.A., Rees M., Senturk L.M., Simoncini T., Stevenson J.C., Stute P., Trémollieres F.A.

Hormone therapy and the prevention of cardiovascular disease and cognitive decline: Where do we stand?

Palabras claves:

Faustino R. Pérez-López, Lambrinoudaki I.

Osteoporosis management in patients with breast cancer: EMAS position statement

Abstract: Aromatase inhibitors (AIs) are the first-line recommended standard of care for postmenopausal estrog

Palabras claves:

adjuvant therapy, Aromatase inhibitors, Bisphosphonates, Breast Cancer, Denosumab, fractures, OSTEOPOROSIS, screening

Ceausu I., Depypere H., Faustino R. Pérez-López, Lambrinoudaki I., Mueck A., Rees M., Senturk L.M., Simoncini T., Stevenson J.C., Stute P., Trémollieres F.A., van der Schouw Y.T.